• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

DNA倍体、p53和HER-2/neu作为子宫内膜癌预后因素的多变量分析。

Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer.

作者信息

Lukes A S, Kohler M F, Pieper C F, Kerns B J, Bentley R, Rodriguez G C, Soper J T, Clarke-Pearson D L, Bast R C, Berchuck A

机构信息

Department of Obstetrics and Gynecology/Division of Gynecologic Oncology, Duke Comprehensive Cancer Center, Durham, North Carolina.

出版信息

Cancer. 1994 May 1;73(9):2380-5. doi: 10.1002/1097-0142(19940501)73:9<2380::aid-cncr2820730922>3.0.co;2-g.

DOI:10.1002/1097-0142(19940501)73:9<2380::aid-cncr2820730922>3.0.co;2-g
PMID:7909491
Abstract

BACKGROUND

Several molecular-genetic alterations in endometrial cancers, including aneuploidy and aberrant expression of p53 and HER-2/neu, have been associated with poor prognosis. To determine the importance of molecular-genetic factors relative to more traditional surgical-pathologic prognostic factors, a multivariable analysis was performed.

METHODS

Immunohistochemical staining for p53, HER-2/neu, estrogen receptor, progesterone receptor, and epidermal growth factor receptor was performed on frozen sections from 100 primary endometrial cancers. DNA ploidy was determined using computerized image analysis of Feulgen-stained touch preparations. In addition, information regarding surgical-pathologic features of the cancers was obtained. Univariable analysis was performed followed by multivariable analysis using Cox's proportional hazards model to identify variables predictive of poor prognosis.

RESULTS

With univariable analysis, race, histologic type, stage, grade, myometrial invasion, estrogen receptor, progesterone receptor, ploidy, p53 and HER-2/neu were predictive of the presence of persistent or recurrent disease. In the multivariable analysis, only International Federation of Gynecology and Obstetrics stage (P = 0.005), grade (P = 0.005), myometrial invasion (P = 0.024), and ploidy (P = 0.028) were significant.

CONCLUSIONS

Among molecular-genetic prognostic factors, DNA ploidy was the most strongly predictive of persistent or recurrent disease.

摘要

背景

子宫内膜癌的几种分子遗传学改变,包括非整倍体以及p53和HER-2/neu的异常表达,均与预后不良相关。为了确定分子遗传学因素相对于更传统的手术病理预后因素的重要性,进行了多变量分析。

方法

对100例原发性子宫内膜癌的冰冻切片进行p53、HER-2/neu、雌激素受体、孕激素受体和表皮生长因子受体的免疫组织化学染色。使用对福尔根染色的触摸涂片进行计算机图像分析来确定DNA倍体。此外,获取了有关癌症手术病理特征的信息。先进行单变量分析,然后使用Cox比例风险模型进行多变量分析,以识别预测预后不良的变量。

结果

单变量分析显示,种族、组织学类型、分期、分级、肌层浸润、雌激素受体、孕激素受体、倍体、p53和HER-2/neu可预测持续性或复发性疾病的存在。多变量分析中,只有国际妇产科联盟分期(P = 0.005)、分级(P = 0.005)、肌层浸润(P = 0.024)和倍体(P = 0.028)具有显著性。

结论

在分子遗传学预后因素中,DNA倍体对持续性或复发性疾病的预测性最强。

相似文献

1
Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer.DNA倍体、p53和HER-2/neu作为子宫内膜癌预后因素的多变量分析。
Cancer. 1994 May 1;73(9):2380-5. doi: 10.1002/1097-0142(19940501)73:9<2380::aid-cncr2820730922>3.0.co;2-g.
2
Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for prediction of poor short term prognosis in breast cancer.对DNA倍体、p53、c-erbB-2蛋白、表皮生长因子受体(EGFR)和类固醇激素受体进行多变量分析,以预测乳腺癌短期预后不良。
Anticancer Res. 1997 Mar-Apr;17(2B):1417-23.
3
Multivariate analysis of bcl-2, apoptosis, P53 and HER-2/neu in breast cancer: a short-term follow-up.乳腺癌中bcl-2、细胞凋亡、P53和HER-2/neu的多变量分析:短期随访
Anticancer Res. 2002 Jul-Aug;22(4):2493-9.
4
The relationship between mutant p53 gene, DNA contents and conventional clinicopathological prognostic variables in cases with endometrial carcinoma.子宫内膜癌病例中突变型p53基因、DNA含量与传统临床病理预后变量之间的关系。
Eur J Gynaecol Oncol. 2005;26(1):64-70.
5
Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for short-term prognosis in breast cancer.DNA倍体、p53、c-erbB-2蛋白、表皮生长因子受体(EGFR)及类固醇激素受体对乳腺癌短期预后的多因素分析
Anticancer Res. 1997 Jul-Aug;17(4B):3091-7.
6
HER-2/neu, p53, and DNA analyses as prognosticators for survival in endometrial carcinoma.HER-2/neu、p53及DNA分析作为子宫内膜癌生存预后指标
Obstet Gynecol. 1995 May;85(5 Pt 1):729-34. doi: 10.1016/0029-7844(95)00037-r.
7
HER-2/neu expression: a major prognostic factor in endometrial cancer.HER-2/neu表达:子宫内膜癌的一个主要预后因素。
Gynecol Oncol. 1992 Nov;47(2):179-85. doi: 10.1016/0090-8258(92)90103-p.
8
Assessment of DNA Ploidy in the ProMisE molecular subgroups of endometrial cancer.评估子宫内膜癌 ProMisE 分子亚组中的 DNA 倍性。
Gynecol Oncol. 2017 Sep;146(3):596-602. doi: 10.1016/j.ygyno.2017.06.020. Epub 2017 Jun 21.
9
Multivariate survival analysis of clinicopathologic features in surgical stage I endometrioid carcinoma including analysis of HER-2/neu expression.Ⅰ期手术切除的子宫内膜样癌临床病理特征的多因素生存分析,包括HER-2/neu表达分析
Am J Obstet Gynecol. 1995 Dec;173(6):1829-34. doi: 10.1016/0002-9378(95)90436-0.
10
Prospective analysis of DNA ploidy, proliferative index and epidermal growth factor receptor as prognostic factors for pretreated uterine cancer.对DNA倍体、增殖指数和表皮生长因子受体作为预处理子宫癌预后因素的前瞻性分析。
Oncol Rep. 2000 May-Jun;7(3):551-9. doi: 10.3892/or.7.3.551.

引用本文的文献

1
The ErbB Signaling Network and Its Potential Role in Endometrial Cancer.表皮生长因子受体(ErbB)信号网络及其在子宫内膜癌中的潜在作用
Epigenomes. 2023 Oct 1;7(4):24. doi: 10.3390/epigenomes7040024.
2
Diagnostic Algorithmic Proposal Based on Comprehensive Immunohistochemical Evaluation of 297 Invasive Endocervical Adenocarcinomas.基于 297 例浸润性宫颈腺癌的综合免疫组化评估的诊断算法建议。
Am J Surg Pathol. 2018 Aug;42(8):989-1000. doi: 10.1097/PAS.0000000000001090.
3
New concepts for an old problem: the diagnosis of endometrial hyperplasia.
一个老问题的新概念:子宫内膜增生的诊断。
Hum Reprod Update. 2017 Mar 1;23(2):232-254. doi: 10.1093/humupd/dmw042.
4
Gene expression analysis of early stage endometrial cancers reveals unique transcripts associated with grade and histology but not depth of invasion.早期子宫内膜癌的基因表达分析显示,与分级和组织学相关的独特转录本,但与浸润深度无关。
Front Oncol. 2013 Jun 17;3:139. doi: 10.3389/fonc.2013.00139. eCollection 2013.
5
Selected immuno-histochemical markers in curettage specimens and their correlation with final pathologic findings in endometrial cancer patients.刮宫标本中选择的免疫组织化学标志物及其与子宫内膜癌患者最终病理发现的相关性。
Pathol Oncol Res. 2013 Apr;19(2):229-35. doi: 10.1007/s12253-012-9573-1. Epub 2012 Oct 10.
6
Cadherins, catenins and cell cycle regulators: impact on survival in a Gynecologic Oncology Group phase II endometrial cancer trial.钙黏蛋白、连环蛋白和细胞周期调节剂:对妇科肿瘤学组 II 期子宫内膜癌试验中生存的影响。
Gynecol Oncol. 2011 Nov;123(2):320-8. doi: 10.1016/j.ygyno.2011.07.005. Epub 2011 Aug 3.
7
Emerging therapeutic targets in endometrial cancer.子宫内膜癌的新兴治疗靶点。
Nat Rev Clin Oncol. 2011 May;8(5):261-71. doi: 10.1038/nrclinonc.2010.216. Epub 2011 Jan 11.
8
Microarray analysis reveals distinct gene expression profiles among different tumor histology, stage and disease outcomes in endometrial adenocarcinoma.微阵列分析揭示了子宫内膜腺癌在不同肿瘤组织学、分期和疾病结局中的独特基因表达谱。
PLoS One. 2010 Nov 8;5(11):e15415. doi: 10.1371/journal.pone.0015415.s001.
9
Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy.子宫浆液性乳头状癌的基因表达谱:鉴定用于子宫浆液性癌诊断和治疗的新型分子标志物。
Br J Cancer. 2005 Apr 25;92(8):1561-73. doi: 10.1038/sj.bjc.6602480.
10
Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification.不同类型子宫内膜癌的分子遗传途径:从表型分类到基于分子的分类
Virchows Arch. 2004 Mar;444(3):213-23. doi: 10.1007/s00428-003-0947-3. Epub 2004 Jan 28.